The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
RecruitingOBSERVATIONAL
Enrollment
40
Participants
Timeline
Start Date
November 9, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
July 31, 2027
Conditions
Hepatobiliary Malignancy
Trial Locations (1)
200025
RECRUITING
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine, Shanghai
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT06597539 - The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy | Biotech Hunter | Biotech Hunter